Payment overview · 2025
General Payments
$631.26
16 reported records · 5 companies
Healthcare provider profile · identity verified
Rodolfo J Cepero, M.D. P.A.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · SOUTH MIAMI, FL · NPI 1023087921
Verified facts
What the public records show
CMS Open Payments records show Rodolfo J Cepero, M.D. P.A. received $631.26 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $312.25 | 49.5% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $182.37 | 28.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.06 | 9.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.58 | 7.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.00 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $631.26 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $182.37 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.75 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.61 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.69 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 27 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 527 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 127 |
| Alprazolam | Alprazolam | 360 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 92 |
| Losartan Potassium | Losartan Potassium | 332 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 293 | 83 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 271 | 80 |
| Omeprazole | Omeprazole | 236 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 43 |
| Famotidine | Famotidine | 170 | 55 |
| Lisinopril | Lisinopril | 149 | 38 |
| Jardiance | Empagliflozin | 141 | 37 |
| Metformin Hcl | Metformin Hcl | 137 | 45 |
| Ezetimibe | Ezetimibe | 127 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 33 |
| Clonazepam | Clonazepam | 110 | 21 |
| Fenofibrate | Fenofibrate | 107 | 33 |
| Atenolol | Atenolol | 106 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 39 |
| Farxiga | Dapagliflozin Propanediol | 103 | 20 |
| Azithromycin | Azithromycin | 102 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 30 |
| Lorazepam | Lorazepam | 97 | 14 |
| Ozempic | Semaglutide | 97 | 22 |
| Gabapentin | Gabapentin | 95 | 37 |
| Donepezil Hcl | Donepezil Hcl | 90 | 28 |
| Trazodone Hcl | Trazodone Hcl | 87 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 23 |
| Bupropion Xl | Bupropion Hcl | 79 | 21 |
| Temazepam | Temazepam | 74 | 11 |
| Mupirocin | Mupirocin | 73 | 29 |
| Allopurinol | Allopurinol | 71 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 18 |
| Montelukast Sodium | Montelukast Sodium | 70 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 48 |
| Azelastine Hcl | Azelastine Hcl | 63 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 21 |
| Rybelsus | Semaglutide | 54 | 15 |
| Sertraline Hcl | Sertraline Hcl | 54 | 18 |
| Carvedilol | Carvedilol | 53 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 23 |
| Eszopiclone | Eszopiclone | 52 | 13 |
| Glimepiride | Glimepiride | 51 | 15 |
| Eliquis | Apixaban | 50 | 18 |
| Ketoconazole | Ketoconazole | 47 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 27 |
| Tradjenta | Linagliptin | 46 | 11 |
| Furosemide | Furosemide | 44 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 11 |
| Folic Acid | Folic Acid | 42 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 41 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 40 | 13 |
| Linzess | Linaclotide | 40 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 39 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Telmisartan | Telmisartan | 37 | suppressed |
| Finasteride | Finasteride | 36 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 22 |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Meloxicam | Meloxicam | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 15 |
| Fluconazole | Fluconazole | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Prednisone | Prednisone | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Ciclopirox | Ciclopirox | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 15 |
| Hydrocortisone | Hydrocortisone | 26 | 11 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Terconazole | Terconazole | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Benzonatate | Benzonatate | 16 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $631.26 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, JARDIANCE, Kerendia, Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error